semaglutide and type 1 diabetes in Adults with Obesity Clinical trials show semaglutide may

In India, the patent for semaglutide is set to expire in March 2026, and at least 15 drugmakers are vying to tap the estimated 409 million opportunity over the next 12-15 months, according to Systematix Institutional Research

Ideal candidates are in good general health and possess realistic expectations for what this therapy can achieve

About half of people who stopped taking the drug did so as a result of side-effects mostly gastrointestinal problems

However, persistent or severe infections may warrant temporary dose reduction or brief treatment pause

Reddit sentiment skews positive, and patients call out efficiency, affordability, and the use of reputable pharmacies, alongside minor complaints about the portal and communication

E., and Konrad, T